GlassScriptPhysician profile
Hasan Shahab
NPI 1134320500
$1,521.10
in general payments reported to CMS, 2019-2025
23 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.47 · 2020: $37.07 · 2021: $255 · 2022: $250 · 2023: $159 · 2024: $469 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814 · Education: $85.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.09 |
| Education | $85.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $369.04 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $218.30 | 2021-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $134.97 | 2019-2024 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $113.46 | 2024 | |
| Fresenius USA Marketing, INC. | $85.97 | 2022-2024 | |
| Aurinia Pharma U.S., INC. | $74.21 | 2021-2024 | Lupkynis |
| Travere Therapeutics, INC. | $57.89 | 2025 | Filspari |
| Opko Pharmaceuticals, LLC | $53.16 | 2023-2024 | Rayaldee |
| Amgen INC. | $46.73 | 2019-2024 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $46.72 | 2021-2023 | |
| Glaxosmithkline, LLC. | $46.22 | 2023-2025 | Arexvy, Shingrix, Benlysta |
| Daiichi Sankyo INC. | $37.84 | 2021 | |
| Calliditas Therapeutics US INC. | $37.39 | 2023-2024 | Tarpeyo |
| Leadiant Biosciences, INC. | $24.08 | 2024 | Carnitor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.32 | 2024 | Trulance, Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $22.15 | 2025 | Defencath |
| Genzyme Corporation | $22.00 | 2024 | |
| Medtronic, INC. | $20.53 | 2025 | Symplicity G3 |
| Ardelyx, INC. | $19.66 | 2024 | Ibsrela |
| Novo Nordisk INC | $18.22 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.84 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $17.72 | 2023 | Jynarque |
| Janssen Pharmaceuticals, INC | $14.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hasan Shahab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.